High Throughput Screening of Vaccine Based on 3Dmicroflu™

CD BioSciences is a growing life science company focusing on 3D bioprinting fields such as bio-ink design, 3D printing technology platform development and in vitro research micro-models customization. Here, our experienced experts can provide you with a series of 3d printing bioinks and solutions based on 3Dmicroflu™ technology platform for you to choose from according to your project needs. In the process of drug development, no matter what type of drug, models are needed for the initial drug screening. CD BioSciences can help you achieve high throughput in drug screening by replacing inaccurate 2D cell and animal models. Do you consider choosing 3Dmicroflu™ technology platform to advance your in vitro drug screening process? The following shows the application of 3Dmicroflu™ technology platform in advancing the vaccine development process.

Overview of vaccine R&D

Vaccines are biological products that have an important preventive effect on infectious diseases , which can have a significant suppressive effect on outbreaks and new infectious diseases. Vaccination is also an effective way to interrupt the spread of infectious diseases. As shown in the table below, various technical routes can be used in the development of vaccines based on different principles and through different methods of virus interruption.

Vaccine R&D Classification		Features and Advantages
Inactivated vaccine		Reliable technology, fast R&D, good safety, easy to use
Viral vector vaccine (replicative, non-replicative)		Gene technology induced cellular immunity, fast development, easy production and preparation, nasal vaccination possible
Recombinant protein vaccine (recombinant protein, VLP)		Artificial design and gene synthesis, easy purification, low cost
Nucleic acid vaccine (mRNA, DNA)		Fast R&D, short production cycle, easy to scale up production, low cost
Live attenuated vaccine		Good immunogenicity, good persistence of immunity

Table. 1. Classification of vaccines and their respective characteristics.

According to the table, inactivated vaccines, mRNA vaccines and adenovirus vector vaccines are the three most widely used and produced vaccines. The recombinant protein vaccine is the vaccine with the most clinical trials. Inactivated vaccines are the traditional vaccine technology with mature process and stable quality, which are characterized by high safety, good accessibility and clear efficacy. At CD BioSciences, our experienced experts can provide you with 3D printed model solutions based on 3Dmicroflu™ according to your project needs in order to better advance your vaccine development process.

3Dmicroflu™ for the construction of the high-throughput in vitro vaccines screening micro-models

The common mechanism by which the body develops resistance to disease as a result of vaccination is actually the process of acquired immunity. Vaccines have pathogen-like properties and target a series of immune organs such as thymus, lymph nodes, spleen, bone marrow, tonsils, etc. The in vitro screening process has always been an important step in the development of vaccines. Physiologically appropriate micro-models are the best choice to replace animal models to reduce the screening tolerance and speed up the screening process. Here, CD BioSciences can provide you with a high-resolution 3D bioprinting technology platform called 3Dmicroflu™ to help you build various types of immune organ micro-models that can meet your vaccine screening needs and accelerate your in vitro vaccine screening process. The process of involving 3Dmicroflu™ technology platform in vaccine development is illustrated below.

Fig. 1. 3Dmicroflu™ technology platform is involved in the construction of immune organs for the rapid screening process of vaccines.

High-resolution 3Dmicroflu™ technology platform from CD BioSciences can assist you in these aspects of your vaccine screening efforts.

• Participate in the design and construction of the immune organ (custom/conventional) required for your project.
• Simulate and restore the process of vaccine activation of immune target organs to produce acquired immunity in a physiological state.
• Validate the immune efficacy of various vaccine candidates to rapidly screen for vaccines with potential applications.

Immune organ micro-models constructed with the participation of 3Dmicroflu™ technology platform can better reflect the real physiological characteristics than animal models that are much different from human physiological states. Therefore, 3Dmicroflu™ technology platform can help you to avoid the situation that the vaccine development process is significantly slowed down due to the difference in the effect of the vaccine in animal models and humans. On the contrary, 3Dmicroflu™ technology platform will greatly accelerate your vaccine screening process and achieve high throughput screening.

If you have a need for the 3Dmicroflu™ technology platform for high-throughput screening of vaccines in your drug development program, please feel free to contact us for customization of the immune organ and system. We always hope that 3Dmicroflu™ technology platform will provide great assistance and guidance to your drug development process.